Summary of new trials presented at the 2021 American College of Cardiology Scientific Sessions.

Abstract

Unlike the PARADIGM HF study, which showed that sacubitril/ valsartan is superior to enalapril in reducing mortality and hospitalization for heart failure (HF) in patients with left ventricular ejection fraction (LVEF) of <_40%; the PARADISE-MI trial, which investigated sacubitril/valsartan compared with ramipril in patients following acute myocardial infraction (AMI) and LVEF of <_40% (without prior HF) showed no difference in the primary endpoint of cardiovascular death, first HF-hospitalization, or outpatient HF between sacubitril/ valsartan and ramipril. However, trends towards benefit were seen in the sacubitril/valsartan group with numerically lower rate of events.